Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10111520 | 0.88 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2CA14CYP2C19KMT2A | |
| SCHEMBL27853893 | 0.88 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2CA14CYP2C19KMT2A | |
| SCHEMBL10464095 | 0.84 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL21578228 | 0.84 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2CA14CA12KMT2A | |
| SCHEMBL16209947 | 0.80 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2KMT2ACA2 | |
| SCHEMBL11418641 | 0.79 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2CA14CYP2C19CA12 | |
| SCHEMBL28271774 | 0.77 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2CA14CYP2C19CA12 | |
| Potassium Ion SCHEMBL11417823 | 0.77 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2CA14CYP2C19CA12 | |
| SCHEMBL11417834 | 0.77 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2CA14CYP2C19CA12 | |
| SCHEMBL1009849 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10060033-B2 | Precursors for the production of thin oxide layers and the use thereof | MERCK PATENT GMBH (DE) | 2018-08-28 | — | — | US | claimed |
| EP-3041847-B1 | PRECURSORS FOR THE PRODUCTION OF THIN OXIDE LAYERS AND THE USE THEREOF | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | claimed |
| US-20160208386-A1 | PRECURSORS FOR THE PRODUCTION OF THIN OXIDE LAYERS AND THE USE THEREOF | MERCK PATENT GMBH (DE) | 2016-07-21 | — | — | US | claimed |
| CN-119915922-A | Method for identifying and judging characteristic precursors of disinfection byproducts in drinking water containing new pollutants | 山东建筑大学 | 2025-05-02 | — | — | CN | disclosed |
| US-12258349-B2 | Anti-viral drug | DORING INTERNATIONAL GMBH (CH) | 2025-03-25 | — | — | US | disclosed |
| CN-117088818-A | Synthesis method of 4, 6-dichloro-2-propylthio-5-aminopyrimidine | 河北博伦特药业有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20220298164-A1 | ANTI-VIRAL DRUG | DORING INTERNATIONAL GMBH (CN) | 2022-09-22 | — | — | US | disclosed |
| US-11370797-B2 | Anti-viral drug | DORING INTERNATIONAL GMBH (CH) | 2022-06-28 | — | — | US | disclosed |
| US-10060033-B2 | Precursors for the production of thin oxide layers and the use thereof | MERCK PATENT GMBH (DE) | 2018-08-28 | — | — | US | disclosed |
| EP-3041847-B1 | PRECURSORS FOR THE PRODUCTION OF THIN OXIDE LAYERS AND THE USE THEREOF | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-20160208386-A1 | PRECURSORS FOR THE PRODUCTION OF THIN OXIDE LAYERS AND THE USE THEREOF | MERCK PATENT GMBH (DE) | 2016-07-21 | — | — | US | disclosed |
| WO-2010085581-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085581-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085582-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085582-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20090312560-A1 | PROCESSES FOR MAKING PREGABALIN AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2009-12-17 | — | — | US | disclosed |
| WO-2009149928-A1 | PROCESSES FOR MAKING PREGABALIN AND INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2009-12-17 | — | — | WO | disclosed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| US-3939184-A | Production of carbonyl compounds substituted in α-position | BADISCHE ANILIN- & SODA-FABRIK AKTIENGESELLSCHAFT (DT) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298164-A1 | ANTI-VIRAL DRUG | ZC3HAV1, ZC3HAV1L, SARS1 | ALDH1A1 1309/4885SMN1; SMN2 2218/4885CA14 885/4885 |
| US-11370797-B2 | Anti-viral drug | NSUN3, EIF2AK2, NSUN2 | ALDH1A1 1794/4885SMN1; SMN2 498/4885CA14 3687/4885 |
| US-20090312560-A1 | PROCESSES FOR MAKING PREGABALIN AND INTERMEDIATES THEREFOR | GABRB2, GABRB1, GABRB3 | ALDH1A1 510/4885SMN1; SMN2 3905/4885CA14 2143/4885 |
| US-12258349-B2 | Anti-viral drug | ZC3HAV1, ZC3HAV1L, SARS1 | ALDH1A1 1309/4885SMN1; SMN2 2218/4885CA14 885/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | ALDH1A1 170/4885SMN1; SMN2 2022/4885CA14 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.